NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia Presents Data from the FLEX Real World Evidence Trial in Seven Posters at ASCO 2022, Showcasing the Power of Its 30,000-Patient Breast Cancer Genome Project
Data show MammaPrint® is the first and most comprehensive FDA-cleared test for early breast cancer resulting in the ability to identify women who may be over- or under-treated if treatment decisions relied on the 21-gene assay Read More
Agendia Presents Data at ASCO 2022 Pointing to New Signature ImPrint Immunotherapy Prediction and Expansion of Proprietary Genomic Tests’ Utility to Identify Patients Who Will Benefit Most from Specific Treatments
Data demonstrate Research Use Only ImPrint test’s ability to identify patients with high risk early breast cancer who may benefit from PD-1/PD-L1 checkpoint inhibition IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS - June 4, 2022 – Read More
Agendia Achieves Historic Milestone of Enrolling 10,000 Patients in FLEX, the Largest-Ever Prospective, Real-World-Evidence Trial for Patients With Early Stage Breast Cancer
Company to present multiple recent Registry sub-studies driving cancer care innovation at ASCO 2022 IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – May 25, 2022 – Agendia, Inc., a commercial-stage company focused on improving outcomes for Read More
Agendia Demonstrates Accessibility and Affordability of MammaPrint and BluePrint in Europe at ESMO Breast Cancer 2022
Next-generation sequencing version of MammaPrint and BluePrint enables decentralized testing in CE-mark jurisdictions like Germany Analysis for Belgian Health Care Package shows MammaPrint yields cost-savings for breast cancer care systemically IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., Read More
Agendia to Deliver Robust Suite of Data Advancing Breast Cancer Care at ASCO 2022
Company showcases pipeline developments and sub-studies from the revolutionary FLEX Registry with posters focused on patient-centric insights Two oral discussion sessions to focus on RUO ImPrint immune signature and BluePrint® whole transcriptomic analysis in Black Read More
GenomeWeb – Agendia Offering AI-Enabled Genomic Test for Breast Cancer in Brazil as it Eyes Global Market
January 27, 2022 By Leo O’Connor NEW YORK ─ As part of its effort to gain regulatory clearance in the US and beyond, Agendia has begun offering early access to a digital testing platform for patients Read More
Agendia Study Demonstrates MammaPrint® and BluePrint® Capture Full Spectrum of Early Breast Cancer Biology, Providing Opportunity for Highly Individualized Treatment
New analysis in peer-reviewed journal Genes, Chromosomes and Cancer further establishes that MammaPrint and BluePrint both comprehensively represent and capture the 10 hallmarks of cancer in early-stage breast cancer Study validates genomic basis of Read More
